Shots:
- Astellas has entered into a collaboration agreement with Chromatin Bioscience to design cell-selective synthetic promoters
- As per the agreement, Chromatin will utilize its chromatinLENS platform to develop cell-selective synthetic promoters for Astellas’ target profile, allowing precise & durable gene expression in specific cells
- chromatinLENS platform identifies gene regulatory elements from the dark genome & designs synthetic promoters for targeted use across therapeutics, agritech, industrial biotech as well as bioprocessing sectors
Ref: Prnewswire | Image: Chromatin Bioscience & Astellas
Related News:- Astellas to Establish Joint Venture with YASKAWA for Cell Therapy Manufacturing
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
